• Science
    • Scientific Overview
    • Rett Syndrome
    • Oncology
    • Wilson Disease
  • Pipeline
  • Team
  • News
  • Careers
  • Contact
DepYmed
  • Science
    • Scientific Overview
    • Rett Syndrome
    • Oncology
    • Wilson Disease
  • Pipeline
  • Team
  • News
  • Careers
  • Contact
Shape Divider - Style triangle

DepYmed News

Top Stories

DepYmed Receives Clearance from U.S. Food and Drug Administration to Initiate Phase 1 Clinical Trial for DPM-1003 for the Treatment of Rett Syndrome
By DepYmed, Inc. | March 19, 2024 
READ MORE
DepYmed to Meet with Investors at the BIO CEO and Investor Conference
By DepYmed, Inc. | February 21, 2024 
READ MORE
DepYmed to Meet with Investors at the 34th Annual Oppenheimer Healthcare Life Sciences Conference
By DepYmed, Inc. | February 7, 2024 
READ MORE
DepYmed to Meet with Investors at the Life Sciences Summit in New York City October 11, 2023
By DepYmed, Inc. | October 3, 2023 
READ MORE
DepYmed to Meet with Investors  at the BioFuture Conference in New York City October 4-6, 2023
By DepYmed, Inc. | September 27, 2023 
READ MORE
DepYmed to Meet with Investors  at the LSX World Congress USA in Boston on September 13-14, 2023
By DepYmed, Inc. | September 7, 2023 
READ MORE
DepYmed Presents Development Update for its Small Molecule PTP1B Inhibitor Program, DPM-1003, at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | June 14, 2023 
READ MORE
DepYmed to Present Early Data on Its Small Molecule PTP1B Inhibitor Program at the 2023 IRSF Rett Syndrome Scientific Meeting
By DepYmed, Inc. | May 31, 2023 
READ MORE
DepYmed Receives European Medicines Agency Orphan Drug Designation for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
By DepYmed, Inc. | November 16, 2022 
READ MORE
DepYmed Receives FDA Orphan Drug Designation for Clinical Candidate DPM-1001 for the Treatment of Wilson Disease
By DepYmed, Inc. | May 23, 2022 
READ MORE
DepYmed Receives FDA Rare Pediatric Disease and Orphan Drug Designations for Its Lead Clinical Candidate for the Treatment of Rett Syndrome
By DepYmed, Inc. | May 3, 2022 
READ MORE
 Role of a New Generation of PTP1B Inhibitors Against a Novel Intracellular Checkpoint in Cancer
By DepYmed, Inc. | March 10, 2022 
READ MORE
 DepYmed Appoints Peter Van Ess, Pharm.D., Ph.D. as VP of Early Development
By DepYmed, Inc. | August 5, 2021 
READ MORE
Depymed, Inc. Announces $8.3 Million Financing
By DepYmed, Inc. | April 7, 2021 
READ MORE
Shape Divider - Style triangle

Archived News

  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
<
>
​June 29, 2018 (DepYmed, Inc) 
DepYmed’s Developmental Compound, DPM-1001, May Lead to a Potential Treatment for Wilson’s Disease
​
​
June 27, 2018 (Cold Spring Harbor Laboratory)
Progress toward improved Wilson’s disease drug
March 24, 2017 (InnovateLI)
​2017 Innovator of the Year Awards

 
March 22, 2017 (InnovateLI)
Here’s to the winners
October 28, 2016 (InnovateLI)
CSHL spinoff earns $2M TopSpin buy-in

 
October 28, 2016 (Newsday - Business)
LI cancer treatment firm gets $2 million in venture funding

​
October 26, 2016 (DepYmed, Inc) 
DepYmed, Inc. Announces $2 Million Financing

December 24, 2015 (Newsday - Business)
DepYmed snags $100,000 to develop new breast cancer drug

​
December 23, 2015 (Northwell Health
Accelerate Long Island and the Long Island Emerging Technologies Fund Announce $50,000 Grant and $50,000 Investment in DepYmed

​
December 22, 2015​ (InnovateLI)
D​epYme​d wins Accelerate funding
​

March 31, 2015 (Accelerate LI)
Accelerate LI Announces 14 Hottest Startups


March 17, 2015 (InnovateLI)
Clinical trials for DepYmed


February 17, 2015 (DepYmed, Inc) 
DepYmed, Inc. Announces Appointment of New President and CEO
May 21, 2014 (Cold Spring Harbor Laboratory)
Team reports validation of potentially powerful new way to treat HER2-positive breast cancer
Shape Divider - Style triangle

Publications

Connecting copper and cancer: from transition metal signalling to metalloplasia
READ MORE
DPM-1001 decreased copper levels and ameliorated deficits in a mouse model of Wilson’s disease
READ MORE
PTP1B is an intracellular checkpoint that limits T cell and CAR T cell anti-tumor immunity
READ MORE
A potent, selective, and orally bioavailable inhibitor of the protein-tyrosine phosphatase PTP1B improves insulin and leptin signaling in animal models
READ MORE
Shape Divider - Style triangle
DepYmed, Inc.
3 Bioscience Park Drive
Farmingdale, NY 11735
@ 2022 DepYmed, Inc.
  • Science
    • Scientific Overview
    • Rett Syndrome
    • Oncology
    • Wilson Disease
  • Pipeline
  • Team
  • News
  • Careers
  • Contact